Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

IMPORTANCE: Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark clinical trials that led to the use of pembrolizumab as standard of care in advanced non–small cell lung cancer (NSCLC) exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehgal, Kartik, Gill, Ritu R., Widick, Page, Bindal, Poorva, McDonald, Danielle C., Shea, Meghan, Rangachari, Deepa, Costa, Daniel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879233/
https://www.ncbi.nlm.nih.gov/pubmed/33570575
http://dx.doi.org/10.1001/jamanetworkopen.2020.37120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879233/
https://www.ncbi.nlm.nih.gov/pubmed/33570575
http://dx.doi.org/10.1001/jamanetworkopen.2020.37120

Ejemplares similares